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Cytotoxic T lymphocytes (CTL) can control some viral infections and may be important in the control of
lentiviruses, including human immunodeficiency virus type 1. Since there is limited evidence for an in vivo role
of CTL in control of lentiviruses, dissection of immune mechanisms in animal lentiviral infections may provide
needed information. Horses infected with equine infectious anemia virus (EIAV), a lentivirus, have acute
plasma viremia which is terminated in immunocompetent horses. Viremic episodes may recur, but most horses
ultimately control infection and become asymptomatic carriers. To begin dissection of the immune mechanisms
involved in EIAV control, peripheral blood mononuclear cells (PBMC) from infected horses were evaluated for
CTL to EIAV-infected cells. By using noninfected and EIAV-infected autologous equine kidney (EK) cells in
5"Cr-release assays, EIAV-specific cytotoxic activity was detected in unstimulated PBMC from three infected
horses. The EIAV-specific cytotoxic activity was major histocompatibility complex (MHC) restricted, as
determined by assaying EIAV-infected heterologous EK targets, and was mediated by CD8+ T lymphocytes, as
determined by depleting these cells by a panning procedure with an anti-CD8 monoclonal antibody.
MHC-restricted CD8+ CTL in unstimulated PBMC from infected horses caused significant specific lysis of
autologous EK cells infected with recombinant vaccinia viruses expressing EIAV genes, either env or gag plus
5' pol. The EIAV-specific MHC-restricted CD8+ CTL were detected in two EIAV-infected horses within a few
days after plasma viremia occurred and were present after viremia was terminated. The detection of these
immune effector cells in EIAV-infected horses permits further studies to determine their in vivo role.
Among lentivirus infections, the disease caused by equine
infectious anemia virus (EIAV) has distinctive features during
both the acute clinical and the subsequent asymptomatic
carrier stages. Horses with EIAV have an initial plasma
viremia and associated fever, anemia, and thrombocytopenia
occurring as early as I to 2 weeks after infection (4, 19, 38, 42).
The initial viremia is usually terminated (19, 42), and viremic
episodes and clinical disease of a duration of several days may
recur. Occurrence of viremic episodes correlates with the
appearance of viral antigenic variants which are resistant to
existing neutralizing antibody (21, 35, 40). Despite antigenic
variation of epitopes recognized by neutralizing antibody (21,
35) and other possible mechanisms of viral escape from
immune responses, most horses control EIAV and become
clinically quiescent virus carriers (5). These carriers have
extremely small amounts of virus in their blood (6), indicating
that the virus is effectively controlled.
The mechanisms by which horses eventually control EIAV
are unknown, although evidence indicates that immune responses are involved. Foals with genetically transmitted severe
combined immunodeficiency disorder and lacking only B- and
T-lymphocyte function are unable to clear the initial viremia
associated with EIAV infection (42). That EIAV carriers
become viremic within 5 to 7 days following either corticosteroid or cyclophosphamide treatment further suggests virus

control by immune responses (20). Several immune mechanisms directed against viral proteins could be involved in
control of EIAV. Antibodies to Env protein epitopes cause
either viral neutralization (9, 15) or possible destruction of
cells expressing Env or other proteins by antibody-dependent
cellular cytotoxicity (22) or complement lysis (12). In human
immunodeficiency virus type 1 (HIV-1)-infected humans, cytotoxic T lymphocytes (CTL) recognize epitopes from several
viral proteins, including Env, Gag, Pol, Nef, and Vif proteins
(36, 39, 44, 50), and CTL recognizing epitopes on similar
simian immunodeficiency virus (SIV) proteins are present in
infected rhesus monkeys (2, 31, 52, 53).
Knowledge of the relative roles of the various immune
responses in preventing lentivirus infections and in controlling
infections once they occur is needed to design effective vaccines and immunologic interventions (13). Thus, CTL were
investigated to begin dissecting immune responses involved in
the termination of plasma viremia in acute EIAV infection and
in EIAV control in asymptomatic carriers. Since major histocompatibility complex (MHC)-restricted CTL to EIAV-infected cells had not been clearly described, cell targets for
demonstrating cytotoxicity were identified, and an assay was
developed to detect CTL in unstimulated peripheral blood
mononuclear cells (PBMC) from infected horses. MHC-restricted cytotoxic activity was found in unstimulated PBMC
that caused significant specific lysis of EIAV-infected equine
kidney (EK) cell cultures. Depletion of CD8+ T lymphocytes
removed the EIAV-specific MHC-restricted CTL activity. Viral proteins recognized by CTL were determined by using
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autologous EK cells infected with recombinant vaccinia viruses
expressing EIAV genes as targets. MHC-restricted CD8 CTL
caused lysis of targets infected with recombinant vaccinia
viruses expressing EIAV genes, either env or gag plus 5' pol.
MATERIALS AND METHODS
EIAV-infected horses. The horses used were mixed-breed
ponies. One kidney was removed by nephrectomy from a
13-month-old male (H507), and 2 months later the horse was
infected with 107 50% tissue culture infective doses (TCID50)
of EIAVwsU5. EIAVwsU5 is a pathogenic cell culture-adapted
strain isolated after three sequential passages of prototype
EIAV in horses, with the predominant virus type selected by
three limiting dilutions on EK cell cultures from a newborn
foal (34, 37). A percutaneous renal biopsy was taken from a
10-month-old female (H521), and 1 month later, the horse was
infected with 108 TCID50 of EIAVWsU5. Similarly, a renal
biopsy was taken from a 6-year-old male (H525), and 2 weeks
later, the horse was infected with 108 TCID5( of EIAVwsu5.
Rectal temperature was taken daily (three times per week), the
blood packed-cell volume was measured, and plasma virus titer
was determined by using EK cell cultures (37, 42). Blood
thrombocyte counts of H525 were done three times a week.
Target cells for CTL assays. Attempts to demonstrate CTL
in infected horses by using EIAV-infected autologous dermal
fibroblasts as targets were unsuccessful. Subsequent studies
with cultures of undefined EK cells established from renal
tissue (34, 37) obtained by nephrectomy (H507) or biopsy
(H521 and H525) and used in CTL assays at passages 1 to 6
were done. EK cells were infected with 10 TCID50) of EIAVwSu5 per cell for 2 h, washed, and maintained for 6 to 21 days
before use. The percentage of EIAV-infected cells was determined by direct immunofluorescence (7, 37), and in this study,
the mean was 61% (range, 55 to 72%).
CTL assay. Target cells (2 x 104) in collagen-coated wells of
a 96-well plate were incubated for 24 h at 37°C with 5% CO,
before 5'Cr labeling. Coating was done with water (25 [I per
well) containing 1 mg of calf collagen (Sigma Chemical Co., St.
Louis, Mo.) per ml, and then wells were air dried. To infect EK
cell targets with vaccinia viruses, seeded cells were incubated
for 7 h; infected with 10 PFU of VSC11, VEnv2, or VGag/PR
per cell; and incubated for 17 h before 5'Cr labeling. Target
cells were labeled for 90 min with 5 p.Ci of 5'Cr per well in 100
[LI of Dulbecco modified Eagle medium with 5% calf serum.
PBMC were isolated, and viability was determined (5 1). Effector/target (E:T) cell ratios of 10:1 and 50:1 were incubated for
6 or 17 h, and 100 pL. of supernatant was removed to determine
5'Cr release. The formula percent specific lysis = [(E -S)(M
- S)] x 100 (48), where E = the mean of six test wells, S =
the mean spontaneous release from six target cell wells without
effector cells, and M = the mean maximal release from six
target cells wells with 3% Triton X-100, was used. The formula
used to calculate standard error (SE) of the percent specific
lysis accounts for the variability of E, S, and M (48).
Recombinant vaccinia viruses expressing EIAVWSU5 genes.
One recombinant vaccinia virus (VGag/PR) which contains
EIAV gag and 5'pol and expresses a 55-kDa Gag precursor, an
82-kDa Gag/Pol fusion protein including protease (PR), and
subviral particles containing processed p26 (30) was used.
Recombinants expressing env were made from overlapping
cDNA clones containing the complete EIAVWSU5 env gene
(29). The env gene was assembled in the SmaI cloning site of
pSCII by using the 2,400-nucleotide SphI-EcoRI fragment
from one cDNA clone, the 400-nucleotide BamHI-SphI fragment from another clone, and an adaptor with a 3' BamHI site
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and a 5' ATG translation initiation codon. The synthetic
adaptor had env nucleotides 1262 to 1286 (45) in the 5'-to-3'
strand and 1262 to 1291 in the 3'-to-5' strand. Fragment
orientation in pEIASE was verified by restriction endonuclease
mapping, and the presence of the adaptor was verified by
sequencing.
Recombinant vaccinia virus VEnvl was made with pEIASE
to express the env gene. VEnv2 was the same as VEnvI except
that site-directed mutagenesis (49) was used to make a singlebase mutation in pEIASE to remove an early vaccinia virus
transcription terminator signal, TTTTTNT (8). Sequencing
confirmed that a synonymous C was substituted for T at
position 2080 and that no other changes were introduced.
VSC1 I was a control recombinant made with pSC1 1. After
recombination with WR strain vaccinia virus (26), recombinants were identified by ,B-galactosidase expression (3), and
Env protein expression was verified by immunoblotting. Selected recombinants were plaque purified three times on
BSC-1 cells.
Immunoblots to detect Env proteins. EK cell cultures in
15(-cm2 flasks with Dulbecco modified Eagle medium and 5%
bovine serum were infected with 10 PFU of VEnvl, VEnv2, or
VSC1 1 per cell. Ten minutes before infection, medium from
one group of flasks was removed, and medium with 40 p.g of
cytosine arabinoside per ml was added (8). Cells were removed
after incubation for 2, 4, or 24 h at 37°C; washed three times
with phosphate-buffered saline (PBS); and lysed on ice for 30
min in 50 mM Tris hydrochloride (pH 8.0) with 5 mM EDTA,
5 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, 0.1
mM N-tosyl-L-lysine chloromethyl ketone, and 0.5% Nonidet
P-40. Lysates were cleared by centrifugation (9,000 x g for 5
min), separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, transferred to nitrocellulose, and immunoblotted with equine monoclonal antibodies (MAbs) from
equine-murine xenohybridomas (41). Equine MAb 30/8.12
recognizes EIAV SU (gp9O), and MAb 30/249.2 recognizes
TM (gp45) (41). Bound MAb was detected with antibodies to
equine immunoglobulin conjugated to horseradish peroxidase
and visualized by chemiluminescence (28).
Northern (RNA) blots of RNA from recombinant vaccinia
virus-infected cells. After infection of EK cells with VEnvl or
VEnv2, 100 p.g of cycloheximide per ml was added (8).
Cultures were incubated at 37°C for 2 h and then rinsed, and
cells were removed by scraping. Total RNA was extracted with
guanidine thiocyanate and homogenization and then centrifuged through cesium chloride (47). Ten micrograms of RNA
per lane was separated in a 1.2% formaldehyde gel, transferred
to GeneScreen Plus nitrocellulose, baked at 80°C for 2 h, and
hybridized with a 329P-labeled BamHI-Xbal env fragment (1).
Depletion of CD8+ T lymphocytes from PBMC. Isolated
PBMC were depleted of CD8+ T lymphocytes by using an
anti-equine CD8 MAb covalently bound to a surface-activated
flask. Briefly, 250 p.g of anti-CD8 MAb HT14A (23) in 5 ml of
0.01 M sodium phosphate-0.15 M NaCl (pH 7.4) (PBS) was
added to MicroCELLector surface-activated cell culture flasks
(Applied Immune Sciences, Santa Clara, Calif.) and incubated
for I h at room temperature. After washing and blocking flasks
with 0.2% bovine serum albumin (BSA) in PBS, 3 x 107
PBMC which had been blocked with 10% autologous serum in
PBS were added to each flask and incubated at room temperature for 1 h. Nonadherent cells were collected for evaluation
and use in CTL assays.
Immunofluorescence flow cytometry. PBMC (107/ml) were
suspended in PBS with 0.5% BSA and 0.02% sodium azide,
both before and after depletion of CD8+ T lymphocytes. Next,
50 .1l of cell suspensions was added to 50 .1l of 15-p.g/ml MAb
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HT14A to equine CD8 (23), 15-p.g/ml MAb HB61A to equine
CD4 (23), or 5-pg/ml fluorochrome-labeled anti-horse immunoglobulin (Chemicon International, Inc., Temecula, Calif.).
After incubation at 4°C for 30 min, cells were washed three
times and pelleted at 4°C for 3 min at 1,500 x g. Cells were
resuspended in 100 ,ul of cold PBS-0.5% BSA-0.02% sodium
azide and incubated at 4°C for 30 min with 100 .1l of 5-pg/ml
fluorescein-conjugated anti-mouse immunoglobulin serum
(Caltag Laboratories, South San Francisco, Calif.) adsorbed
with normal horse serum. After washing, cells were fixed with
2% formaldehyde in PBS and analyzed with a FACScan
equipped with a Consort 32 computer and LYSYS II software
(Becton Dickinson, San Jose, Calif.).
Nucleotide sequence accession number. The EIAVWSUS env
gene sequence has been assigned EMBL accession number
X16988.
RESULTS
EIAV-specific cytotoxic activity in unstimulated PBMC from
infected horses. PBMC from H507, infected with 107 TCID50
of EIAVwsU5, were evaluated for cytotoxic activity on EIAVwsu5-infected autologous EK cells over a 1-year period.
During this period, the horse had antibodies to p26 but was
afebrile (<39°C), and no plasma viremia or anemia was
detected. However, PBMC taken 7 weeks after infection
caused low-level, but significant, specific lysis of EIAV-infected
cells. The percent specific lysis of EIAV-infected EK cells was
defined as significant when it exceeded the percent specific
lysis of noninfected EK cells by 2.5 SE. The maximum specific
lysis (13.5%) occurred with PBMC taken at 27 weeks and used
at an E:T cell ratio of 50:1 for 17 h (Fig. 1). Both 6- and 17-h
assay times resulted in significant specific lysis of EIAVinfected cells by PBMC (Fig. 1). Since percent specific lysis was
higher with 17-h assays, this time was used in subsequent
assays. The range of 5'Cr spontaneous release in most 17-h
assays was 15 to 31%. On the basis of this and a similar range
in a CTL study using 18-h assays (14), assays with a spontaneous release exceeding 32% were not used. Mixtures with E:T
cell ratios of 10:1 and 50:1 were assayed, and EIAV-specific
lysis was always greater with a 50:1 ratio.
Unstimulated PBMC from H521 infected with 108 TCID5,
of EIAVWSU5 caused remarkable specific lysis of EIAVwsU5infected autologous EK cells (Fig. 2). By using an E:T cell ratio
of 50:1, the maximum percent specific lysis of noninfected EK
target cells by PBMC was 5.4% over 100 days (Fig. 2). No
cytotoxic activity was detected in PBMC taken before and 1
week after infection; however, PBMC taken 2 weeks after
infection caused 29.2% specific lysis (Fig. 2). The maximum
specific lysis (55.3%) of EIAVwsU5-infected autologous EK
cells occurred with PBMC taken 7 weeks after infection. The
amount of specific lysis of infected EK cells by PBMC decreased to 13% at 9 weeks and increased again to 27% at 14
weeks after infection (Fig. 2). Plasma viremia was detected in
H521 at 7 to 26 days after infection, with a peak virus titer of
103 8 TCID5(/ml detected on day 9 (Fig. 2). Plasma viremia was
terminated by day 28, and no viremia was detected between
days 28 and 100; day 100 was the last day evaluated. No fever
or anemia were detected in the 100-day observation period.
PBMC from H525 infected with 108 TCID,() of EIAVwSLJ5,
the same dose as for H521, were examined for cytotoxic activity
against EIAVWS55-infected autologous EK cells (Fig. 3).
Unstimulated PBMC from H525, 21 days after infection and at
an E:T cell ratio of 50:1, caused 48.5% specific lysis of
EIAV-infected EK target cells and 2.4% specific lysis of
uninfected EK target cells. Plasma viremia was detected at day
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FIG. 1. EIAV-specific cytotoxicity by unstimulated PBMC from
H507 taken 27 weeks after infection. Six- and 17-h 5'Cr-release assays
were done with noninfected and EIAVwsu5-infected autologous EK
cells. Vertical lines on columns are SEs (48).

8, peaked on day 20 at 102- 'TCID5(/ml, and was terminated by
day 39 (Fig. 3). Thrombocytopenia occurred at day 18 and
reached a minimum of 45,000 platelets per pLI on day 22 (data
not shown). PBMC collected at 42 and 56 days after infection,
times when viremia was terminated and thrombocyte counts
had returned to normal, also caused significant specific lysis of
EIAV-infected EK cells. The cause of relatively high percent
specific lysis of uninfected autologous EK cells on days 28 and
42 (17 and 13%, respectively) is unknown, as lysis of heterologous EK cells did not occur.
MHC restriction of EIAV-specific, PBMC-mediated cytotoxicity. PBMC from H525 at 6 weeks after infection, which
caused 24% specific lysis of autologous EK cells infected with
EIAVWSU5, caused only 2.2% specific lysis of EIAVwsU5infected EK cells from an unrelated horse, H521 (Fig. 4).
Similarly, PBMC from H521 at 4 weeks after infection, which
caused 49.4% specific lysis of EIAVwsU5-infected autologous
EK cells, caused only 5.3% specific lysis of non-MHC-matched
EIAVwsU5 -infected EK cells from an unrelated horse, H507
(Fig. 5). These data indicated that over 90% of the EIAVspecific cytotoxicity was MHC restricted and not attributable to
antibody-dependent cellular cytotoxicity mechanisms including
CD16+ lymphocytes armed with EIAV-specific antibody (44,
52).
Effect of depletion of CD8+ T lymphocytes on EIAV-specific,
MHC-restricted, PBMC-mediated cytotoxicity. CD8+ T lymphocytes were removed from unstimulated PBMC of H525 and
H521 at 10 and 20 weeks after infection, respectively, by a
panning procedure with MAb HT14A to equine CD8. Specific
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FIG. 2. EIAV-specific cytotoxicity by unstimulated PBMC from
H521 over a 100-day observation period after infection. Targets were
noninfected and EIAVwsU5-infected autologous EK cells, E:T cell
ratio was 50:1, and assay time was 17 h. The SE for percent specific
lysis did not exceed 3.0 for either infected or noninfected EK cell
targets. Plasma virus titers were determined by titration in EK cell
cultures (42), and 0 titers are those in which no virus was detected in
six wells inoculated with 50 ,ul of plasma per well (< 1.3 logl0
TCID5,Iml of plasma).

FIG. 3. EIAV-specific cytotoxicity by unstimulated PBMC from
H525 over a 60-day observation period after infection. Targets were
noninfected and EIAVwsu5-infected autologous EK cells, E:T cell
ratio was 50:1, and assay time was 17 h. The SE for percent specific
lysis did not exceed 4 for either infected or noninfected EK cell targets,
except that the SE was 5.5 with infected cells on day 28. Plasma virus
titers were determined by titration in EK cell cultures (42), and 0 titers
are those in which no virus was detected in six wells inoculated with 50
p.l of plasma per well (<1.3 log10 TCID50Jml of plasma).

removal of CD8+ T lymphocytes without affecting other
PBMC lymphocyte subsets was confirmed by fluorescent flow
cytometry with MAb to CD4+ T lymphocytes and antibodies to
immunoglobulin M+ B lymphocytes. PBMC from H525 containing 16% CD8+ T lymphocytes caused 42.3% specific lysis
of EIAVwsu5-infected EK cells, while those PBMC depleted
of CD8+ T lymphocytes (<0.5% CD8+ remaining) caused
10.3% specific lysis of the same target cells (Fig. 6). PBMC
from H521 containing 11% CD8+ T lymphocytes caused
23.8% specific lysis of EIAV-infected EK cells, while those
PBMC depleted of CD8+ T lymphocytes (<0.6% CD8+
remaining) caused 6.6% specific lysis of the same target cells
(Fig. 6). This demonstrated that 72 to 76% of the EIAVspecific, MHC-restricted CTL activity in these PBMC was
mediated by CD8+ T lymphocytes.
Characterization of recombinant vaccinia viruses expressing EIAVWSu5 env. Site-directed mutagenesis was used to alter
a cryptic poxvirus early transcription termination signal in the
EIAVWSU5 env gene used to make VEnv2. Sequence analysis
of the mutated gene in the insertion plasmid demonstrated
that C was substituted for T at nucleotide position 2080, which
should alter the termination signal without changing the
encoded amino acid. Evidence for signal alteration was obtained by comparison of Northern blots of RNA isolated 2 h
after infection of EK cells with VEnv2 or VEnvl (made with
nonmutated env) in the presence of cycloheximide. Cycloheximide was used to inhibit early protein synthesis by the vaccinia
virus P7.5 promoter used to express EIAV env and, thereby,
enhance mRNA accumulation. The major env transcript from
VEnvl-infected EK cells was 0.9 kb (Fig. 7), representing
mRNA truncated by the early termination signal. A minor
transcript of 2.5 kb, the size of the complete env gene if signal

read-through occurred, was also made. In contrast, EK cells
infected with VEnv2 made only the complete 2.5-kb env
transcript (Fig. 7), confirming alteration of the termination
signal.
The Env proteins made by EK cells infected with VEnvl and
VEnv2 (mutated) were compared by immunoblotting with
defined MAb to EIAV SU and TM (41). The amounts of Env
proteins made at 2 and 4 h after infection were less in VEnvlthan in VEnv2-infected cells (Fig. 8); however, similar amounts
of these proteins were present at 24 h. Four hours after
infection, both lysates had proteins reactive with anti-SU MAb
at 125 and 105 kDa (Fig. 8A), interpreted as Env precursor and
SU (43, 46). At 24 h, lysates had an additional unidentified
protein of 62 kDa reactive with anti-SU MAb. Major proteins
reactive with anti-TM MAb appeared after 4 h infection with
VEnv2 and were 125 and 55 kDa. After 24 h, lysates from
VEnvl- and VEnv2-infected cells had major proteins of 125,
49, and 39 kDa reactive with anti-TM MAb (Fig. 8B). These
were interpreted, respectively, as Env precursor, TM, and a
proteolytic product of TM identified as gp35 in other studies
(43). The minor bands reacting with anti-TM MAb in 24-h
lysates and the 55-kDa protein in 4-h VEnv2-infected lysates
were probably Env protein intermediates of proteolytic processing. Cytosine arabinoside was added to VEnvl- and
VEnv2-infected EK cells to inhibit DNA synthesis and,
thereby, late protein synthesis by the vaccinia virus P7.5
promoter that was used to express EIAV env (P7.5 has both
early and late promoter activities [8]). This treatment decreased production of all Env proteins, but the decrease was
more marked in cells infected with VEnvl. This demonstrated
that mutation of the transcription termination signal enhanced
P7.5-promoted early protein synthesis but had little effect on
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FIG. 5. EIAV-specific, MHC-restricted cytotoxicity by unstimulated PBMC from H521 at 4 weeks after infection. Assays were done
for 17 h with autologous (H521) and heterologous (H507) EK cells
targets that were noninfected and EIAVwsU5 infected. Vertical lines
on columns are SEs (48).

late protein synthesis. VEnv2 was used to infect EK target cells
because of these data and because (i) transcription termination
signal removal from HIV-1 env enhanced antibody in mice
immunized with vaccinia virus expressing this gene (8) and (ii)
levels of endogenously processed antigen may determine
whether an epitope and class I MHC complex is efficiently
presented to and recognized by class I-restricted CTL (33).
MHC-restricted CD8+ CTL of vaccinia virus-infected target
cells expressing Env or Gag/PR proteins. PBMC containing
MHC-restricted CD8+ CTL to EIAVwsu5-infected EK cells
were tested for CTL activity on EK cell targets infected with
VEnv2-expressing EIAV env, VGag/PR-expressing gag and 5'
pol genes, or VSC1 1 control recombinant vaccinia virus.
PBMC from H521 at 8 weeks after infection and used at an
E:T cell ratio of 50:1 caused 18.2% specific lysis of VEnv2infected autologous EK cells compared with 9.8% for VSC1 1infected cells (Fig. 9). When the VSC1 1- and VEnv2-infected
cells were treated with UV light for 2 min 17 h after infection
to inhibit vaccinia virus replication during the CTL assay, there
was 1.2 and 10.3Cc specific lysis, respectively (Fig. 9). Studies
with PBMC from H525 taken 6 weeks after infection and used
at an E:T cell ratio of 50:1 caused 32.0 and 13.3% specific lysis
of EIAVwsU5-infected and noninfected autologous EK cells,
respectively (Fig. 10). These PBMC also caused 29.6, 22.6, and
15.7% specific lysis of VEnv2-, VGag/PR-, and VSCI 1-infected autologous EK cells, respcctively (Fig. 10). When the
same H525 PBMC were evaluated on noninfected and EIAVwSu5-, VEnv2-, VGag/PR-, and VSCI 1-infected heterolo-

gous H521 EK cells, the highest specific lysis was 5.5%,
demonstrating that lysis of targets expressing Env and Gag/PR
proteins was also MHC restricted (Fig. 10).

DISCUSSION

EIAV-specific, MHC-restricted CD8+ CTL were demonstrated in unstimulated PBMC from EIAVwsu5-infected
horses. The specificity of CTL for EIAV was demonstrated by
significant specific lysis of EIAVwsu5-infected autologous EK
cells compared with that in noninfected cells. Features of the
described assay that resulted in consistent detection of CTL
were use of EIAV-infected autologous EK cells and incubation
for 17 h with a 50:1 E:T cell ratio. Preliminary experiments
using EIAV-infected autologous dermal fibroblasts were unsuccessful, and this may have resulted from fewer EIAVinfected cells in these cultures. The maximum number of
fibroblasts infected as determined by immunofluorescence in
this and other studies (18) was approximately 30%, while the
mean number of infected EK cells was 61%. The highest
percent specific lysis obtained with autologous EK targets was
55.2%. These targets had 67% EIAV-infected cells and a
spontaneous release of 27.3Cc. Under these conditions, 55.2%
specific lysis may be approaching maximum for this system.
The observation that CT L activity was higher in the two horses
given the highest dose of 108 TCID50 of EIAVWSU5 is consistent with correlations between amount of EIAV inoculum and
clinical disease (17).
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EIAV-specific CTL from infected horses

were

MHC re-

stricted, as demonstrated by the failure of PBMC with high
CTL activity to cause significant specific lysis of EIAVwSs5infected heterologous EK cells from unrelated horses. This
observation is in contrast to earlier results demonstrating that
PBMC from EIAV-infected horses caused direct cytotoxicity
of EIAV-infected heterologous (non-MHC-matched) dermal
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FIG. 7. Autoradiogram of a Northern blot of env transcripts made
by EK cells infected with VEnvl (lane l) and VEnv2 (lane 2) in the
presence of 100 ,ug of cycloheximide per ml. The blot was probed with
a 32P-labeled 827-bp DNA fragment removed from the env gene in
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FIG. 8. Immunoblots of Env proteins expressed by recombinant
vaccinia virus-infected EK cells. (A) Lysates from cells infected with
VSC11 (lane 1), VEnvl (lane 2), and VEnv2 (lane 3) for 2, 4, and 24
h, and for 24 h with cytosine arabinoside (CA) were reacted with
equine MAbs derived from xenohybridomas (41) to EIAV SU (30/
8.12). (B) The same lysates were reacted with equine MAb to EIAV
TM (30/249.2). Migration of the protein (in kilodaltons) is indicated on
the left side of each panel. Similar immunoblots reacted with an
isotype control equine MAb were negative (not shown).

fibroblasts (10). The mechanism of the previously reported
EIAV-specific, non-MHC-restricted equine PBMC cytotoxic
activity is unknown. However, similar observations with PBMC
from human patients seropositive to HIV-1 (27, 44) and
SIV-infected rhesus monkeys (52) have been reported and
attributed to CD16+ MHC class I-unrestricted cells. There is
another report of MHC-restricted specific lysis (6.5 and 8.4%)
of EIAV-infected cells by PBMC from 2 of 11 horses with
acute EIAV infection (11). The target cells used in this report
were autologous PBMC from the EIAV-infected horses stimulated with phytohemagglutinin for 72 h (11). Since EIAV is
not known to replicate in lymphocytes and the number of
infected monocytes was not determined, it is difficult to
interpret these findings. No other reports of PBMC-mediated
cytotoxicity of EIAV-infected cells are known.
That the EIAV-specific, MHC-restricted CTL in PBMC
from infected horses were mediated by CD8+ T lymphocytes
was determined by depletion studies. The CD8+ T lymphocytes were removed from freshly isolated PBMC by a panning
procedure with an anti-CD8 MAb, HT14A (23). Removal of
almost all the detectable CD8+ CTL from PBMC from two
horses (<0.6% of remaining PBMC were CD8+) resulted in 72
and 76% decreases in the MHC-restricted CTL activity. Both
MHC class I-restricted CD8+ CTL and MHC class Il-restricted CD4+ CTL clones have been isolated from PBMC
from HIV-seropositive humans (24, 25). However, most MHCrestricted CTL from HIV-seropositive humans and SIV-infected rhesus monkeys are CD8+ (14, 32, 52).
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FIG. 9. MHC-specific CD8+ CTL in unstimulated PBMC from
H521 at 8 weeks after infection were assayed for cytotoxicity of
autologous EK cells infected with a control recombinant vaccinia virus
(VSC1 1) or one expressing EIAVwSU5 env (VEnv2). UV indicates that
the vaccinia virus-infected cells were treated for 2 min with UV light 17
h after infection. The assay time after adding effector cells was 17 h,
and the spontaneous release of 5'Cr from vaccinia virus-infected cells
without effector cells was <32% of the total released by 3% Triton
X-100. Vertical lines on columns are SEs (48).

FIG. 10. MHC-specific CD8+ CTL in unstimulated PBMC from
H525 at 6 weeks after infection were assayed for cytotoxicity of
autologous EK cells (columns 1 to 5) or heterologous EK cells
(columns 6 to 10) infected with EIAV or recombinant vaccinia viruses.
Target cells in columns 1 and 6 were noninfected, those in 2 and 7 were
EIAVwsu5 infected, those in 3 and 8 were VSC1 1 infected, those 4 and
9 were VEnv2 infected, and those in 5 and 10 were VGag/PR infected.
The E:T ratio was 50:1, assay time was 17 h, and spontaneous release
did not exceed 32%. Vertical lines on columns are SEs (48).

To determine whether EIAV env or gag-5' pol-encoded
proteins were recognized by EIAV-specific, MHC-restricted
CD8+ CTL from PBMC, recombinant vaccinia viruses expressing either EIAVWSUS env or gag plus 5'pol genes were used to
infect autologous EK cell targets. CTL from one horse caused
significant percent specific lysis of target cells expressing Env,
while CTL from a second horse caused significant percent
specific lysis of cells expressing either Env or Gag/PR proteins.
Since EK cell targets infected with recombinant vaccinia
viruses were not evaluated for every assay in which EIAVspecific MHC-restricted CTL were demonstrated, it is not
known whether both horses would have recognized Gag proteins. Furthermore, it is not known whether CTL detected by
reactivity to EIAV-infected cells also recognize epitopes encoded by pol and other genes which encode regulatory proteins
described for CTL from HIV-1-seropositive humans (36, 44)
and SIV-infected rhesus monkeys (2, 36). In many HIV-1 and
SIV studies, CTL have not been detected by using lentivirusinfected target cells, but the studies have used either recombinant vaccinia viruses expressing lentiviral genes or synthetic
peptide-charged target cells. Therefore, it is possible that
further identification of the epitopes recognized on EIAVinfected cells by primary CTL from infected horses that are
successfully controlling EIAV will yield new information.

In conclusion, the demonstration of EIAV-specific, MHCrestricted CD8+ CTL in unstimulated PBMC of EIAV-infected horses as early as 2 weeks after infection and persisting
for several months provides an important system to dissect
unstimulated CTL responses to lentivirus-infected target cells.
The CTL assay, particularly the use of EIAV-infected autologous EK cells, should also be useful in dissecting the mechanism of protective immunity induced by experimental vaccines
to EIAV (16). In fact, the protective immunity induced by
immunization with inactivated EIAV was correlated with
activated T lymphocytes and thought to be mediated in some
horses by CTL (16). Identification of the epitopes recognized
on EIAV-infected cells by CD8+ CTL in unstimulated PBMC
from infected horses in successful remission will facilitate
experiments to induce such responses and to evaluate their
role in protection against EIAV infection and disease.
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